experimental vaccine 2

"Experimental vaccine 2" is a placeholder name used in clinical trials to refer to different investigational vaccine candidates. In one context, it identifies a recombinant COVID-19 vaccine (CHO cells) undergoing Phase I evaluation for safety and tolerability in healthy individuals aged 18 and above. In another context, it refers to a quadrivalent influenza virus subunit vaccine that has completed a clinical trial assessing its safety and immunogenicity in Chinese children aged 6 to 35 months. Due to its use as a generic identifier across distinct trials for different diseases and vaccine types, "experimental vaccine 2" does not represent a single, specific drug but rather various experimental vaccine candidates.